



NCL Method ITA-12

In Vitro Analysis of Nanoparticle Effects on Plasma Coagulation Time

Nanotechnology Characterization Laboratory
Frederick National Laboratory for Cancer Research
Leidos Biomedical Research, Inc.
Frederick, MD 21702
(301) 846-6939
ncl@mail.nih.gov
<https://ncl.cancer.gov>



<https://ncl.cancer.gov>

This protocol assumes an intermediate level of scientific competency with regard to techniques, instrumentation, and safety procedures. Rudimentary assay details have been omitted for the sake of brevity.

Method written by:

Edward Cedrone

Timothy M. Potter

Barry W. Neun

Marina A. Dobrovolskaia*

Nanotechnology Characterization Lab, Cancer Research Technology Program, Frederick
National Laboratory for Cancer Research sponsored by the National Cancer Institute, Frederick,
MD 21702

*- address correspondence to: marina@mail.nih.gov

Protocol adapted from:

Neun, B. W. and Dobrovolskaia, M. A., *Method for in vitro analysis of nanoparticle thrombogenic properties*, in *Characterization of nanoparticles intended for drug delivery*, S. McNeil, Editor. **2011**, Humana Press. p. 225-235. doi: 10.1007/978-1-60327-198-1_24

and

Potter TM, Rodriguez JC, Neun BW, Ilinskaya AN, Cedrone E, Dobrovolskaia MA. In Vitro Assessment of Nanoparticle Effects on Blood Coagulation, in *Characterization of nanoparticles intended for drug delivery*, S. McNeil, Editor. *Methods in Molecular Biology*. Vol. 1628, **2018**, Humana Press, New York, NY. p. 103-124. doi: 10.1007/978-1-4939-7352-1_10

Please cite this protocol as:

Cedrone E, Potter TM, Neun BW, Dobrovolskaia MA, NCL Method ITA-12: In vitro Analysis of Nanoparticle Effects on Plasma Coagulation Time. <https://ncl.cancer.gov/resources/assay-cascade-protocols> DOI: 10.17917/7SF3-7A88

1. Introduction

This document describes a protocol for assessing the effect a nanoparticle formulation may have on plasma coagulation time. Coagulation, i.e., blood clotting, is a highly complex process that involves many components. There are three main pathways for coagulation: intrinsic (also known as the contact activation pathway, because it is activated by a damaged surface); extrinsic (also known as the tissue factor pathway); and the final common pathway. Each pathway can be assessed by a specialized test. For example, the activated partial thromboplastin time (APTT) assay is used to assess the intrinsic pathway, while the prothrombin time (PT) assay is a measure of the extrinsic pathway. Extrinsic and intrinsic pathways converge into common pathway. Thrombin time (TT) is an indicator of the functionality of the final common pathway. Each pathway involves many coagulation factors, some of which overlap between pathways. The APTT assay assesses functionality of factors XII, XI, IX, VIII, X, V, II. The PT assay assesses activity of factors VII, X, V and II. All three assays assess the role of fibrinogen.

2. Principles

This assay describes the analysis of plasma coagulation via three separate tests: prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT). Nanoparticles are incubated with fresh human plasma and assayed for coagulation time, compared to standard controls for each assay, using a coagulometer. When normal plasma is exposed to nanomaterials in vitro, and it results in depletion or inhibition of a certain coagulation factor, a delay in plasma coagulation is expected.

3. Reagents, Materials, and Equipment

Note: The NCL does not endorse any of the suppliers listed below; these reagents were used in the development of the protocol and their inclusion is for informational purposes only. Equivalent supplies from alternate vendors can be substituted. Please note that suppliers may undergo a name change due to a variety of factors. Brands and part numbers typically remain consistent but may also change over time.

3.1 Reagents

- 3.1.1 Human blood from at least 3 donors, anti-coagulated with sodium citrate
- 3.1.2 Neoplastine Cl (Diagnostica Stago, 00667)
- 3.1.3 Thrombin (Diagnostica Stago, 00611)
- 3.1.4 CaCl₂ (0.025M) (Diagnostica Stago, 00367)
- 3.1.5 Owren-Koller Buffer (Diagnostica Stago, 00360)
- 3.1.6 PTT-A (Diagnostica Stago, 00595)
- 3.1.7 CoagControl N+ABN (Diagnostica Stago, 00677)
- 3.1.8 RPMI (GE Life Sciences, HyClone, SH30096.01)
- 3.1.9 PBS (GE Life Sciences, Hyclone, SH 30256.01)

3.2 Materials

- 3.2.1 Metal balls for coagulometer (Diagnostica Stago, 26441)
- 3.2.2 Pipettes covering the range of 0.05 to 10 mL
- 3.2.3 Finntip, 1.25 mL (Fisher, NC0298434)
- 3.2.4 4-well cuvettes (Diagnostica Stago, 38876)

3.3 Equipment

- 3.3.1 Centrifuge capable of operating at 2,500 x g
- 3.3.2 Refrigerator, 2-8°C
- 3.3.3 Diagnostica Stago Art4 Coagulometer

4. Preparation of Study Samples

This assay requires 500 µL of nanoparticles, at a concentration 10X that of the highest tested concentration, dissolved/resuspended in PBS or other relevant media. The concentration is selected based on the plasma concentration of the nanoparticle at the intended therapeutic dose. For the purpose of this protocol this concentration is called “theoretical plasma concentration”. Considerations for estimating theoretical plasma concentration were reviewed elsewhere [1] and are summarized in Box 1 below.

The assay will evaluate 4 concentrations: 10X (or when feasible 100X, 30X or 5X) of the theoretical plasma concentration, theoretical plasma concentration and two 1:5 serial dilutions of the theoretical plasma concentration. When the intended therapeutic concentration is unknown, the highest final concentration is 1 mg/mL or the highest reasonably achievable concentration.

For example, if the final theoretical plasma concentration to be tested is 0.2 mg/mL, then a stock of 20 mg/mL will be prepared and diluted 10-fold (2 mg/mL), followed by two 1:5 serial dilutions (0.4 and 0.08 mg/mL). When 0.1 mL of each of these samples is added to the test tube and mixed with 0.9 mL of plasma, the final nanoparticle concentrations tested in the assay are: 2.0, 0.2, 0.04 and 0.008 mg/mL.

Box 1. Example Calculation to Determine Nanoparticle Concentration for In Vitro Tests

In this example, we assume a mouse dose of 123 mg/kg. Therefore, the scaled equivalent human dose would be:

$$\text{Human dose} = \frac{\text{mouse dose}}{12.3} = \frac{123 \text{ mg/kg}}{12.3} = 10 \text{ mg/kg}$$

Blood volume constitutes approximately 8% of the body weight. Therefore, an average human of 70 kg body weight has approximately 5.6 L of blood. Assuming all the nanoparticle injected goes into the systemic circulation, this provides a rough approximation of the potential maximum nanoparticle concentration in blood, which is used as the in vitro test concentration.

$$\text{in vitro concentration}_{\text{human matrix}} = \frac{\text{human dose}}{\text{human blood volume}} = \frac{70 \text{ kg} * 10 \text{ mg/kg}}{5.6 \text{ L}} = 0.125 \text{ mg/mL}$$

5. Preparation of Test, Normal and Abnormal Control Plasmas

5.1 Test-Plasma

Use freshly collected whole blood within 1 hr after collection. Spin the blood 10 min, 2500xg at 20-22°C; collect plasma and pool from at least 2 donors. Pooled plasma is stable for 8 hr at room temperature. Do not refrigerate or freeze. The assay can also be performed in the plasma from individual donors when needed for mechanistic follow up experiments.

Analyze 2 duplicates (4 total samples) of test-plasma in each of the coagulation assays; run one duplicate before the nanoparticle samples and the second duplicate at the end of each run to verify that the plasma functionality is not affected throughout the duration of the experiment.

5.2 Nanoparticle-Treated Test-Plasma

In a microcentrifuge tube, combine 100 μ L of nanoparticles (as prepared in step 4) and 900 μ L of test plasma; mix well and incubate 30 minutes at 37°C. Prepare three tubes for each test sample (i.e., when each nanoparticle is tested at 4 concentrations, one needs 3 tubes for each concentration, a total 12 tubes per test-nanoparticle).

Note: Insoluble nanoparticles, which can be separated from the bulk plasma by centrifugation may be removed by spinning the test tubes for 5 min at 18,000xg. It is assumed that any proteins involved in the coagulation process and adsorbed onto the particle surface will be removed from the sample in this step and the consequences of such binding on the plasma coagulation pathways will be assessed. Often nanoparticles are soluble or modified with poly(ethylene glycol), and therefore cannot be easily separated from plasma at the end of the incubation step. In this case, the sample analysis proceeds to the next step without centrifugation.

5.3 Normal and Abnormal (Coag N+ABN) Control Plasmas

Reconstitute lyophilized control plasmas with 2 mL of distilled water. Allow the solutions stand to at room temperature 30 min prior to use. Mix thoroughly before use. Keep unused portion refrigerated and use within 48 hr after reconstitution. These plasma samples are used as instrument controls.

5.4. Neoplastin, PTT-A Reagent, and Thrombin (used to initiate plasma coagulation)

These reagents are supplied as lyophilized powders. Reconstitute according to the manufacturer's instructions and use fresh or refrigerate and use within the time specified by the manufacturer.

6. Experimental Procedure

- 6.1 Set-up instrument test parameters for each of the four assays. Refer to the Appendix for a quick list of instrument settings and reagent volumes. Allow the instrument to warm up for 5-10 min prior to use.
- 6.2 Prepare all reagents and warm to 37°C prior to use. Note that lyophilized reagents should be reconstituted at least 30 minutes prior to use.

- 6.3 Place cuvettes into A, B, C and D test rows on the coagulometer (*Note: This protocol is based on the semi-automatic STArt4 coagulometer from Diagnostica Stago [2]. If using a different instrument, please follow the operational guidelines recommended by the instrument manufacturer).*
- 6.4 Add one metal ball into each cuvette and allow cuvette and ball to warm for at least 3 minutes prior to use.
- 6.5 Add 100 µL of control or test plasma to a cuvette when testing PT or thrombin time, and 50 µL when testing APTT (refer to the Appendix for reference). Prepare 2 wells for each test-tube prepared in step 5.2
- 6.6 This step is only for APTT: Add 50 µL of PTT-A reagent to plasma samples in cuvettes.
- 6.7 Start the timer for each of the test rows by pressing the A, B, C or D timer buttons. Ten seconds before time is up, the timer starts beeping. When this happens, immediately transfer cuvettes to PIP row and press PIP button to activate pipettor.
- 6.8 When time is up, add coagulation activation reagent to each cuvette and record coagulation time. Refer to the Appendix for the type of coagulation activation reagent and volume for each of the four assays.

7. Calculations and Data Interpretation

- 7.1 A Percent Coefficient of Variation should be calculated for each control or test according to the following formula: $\%CV = SD/Mean \times 100\%$
- 7.2. Normal and Abnormal control plasma should coagulate within the time established by the certifying laboratory (e.g., for the most batches of control plasmas normal coagulation time in the PT assay is ≤ 13.4 seconds, APTT is ≤ 34.1 second and Thrombin is ≤ 21 seconds; abnormal control plasma coagulation time should be above these limits). When normal and abnormal control perform as described above and untreated plasma sample coagulates within normal time limits, both the instrument and the test plasma are qualified for the use in this test.

- 7.3. Nanoparticles have no effect on the assay coagulation cascade when coagulation time of the test plasma samples after exposure to nanoparticles is within the normal limits.
- 7.4. Prolongation of the plasma coagulation time in plasma samples exposed to nanoparticles suggests that test-particle either deplete or inhibit coagulation factors. There is no guidance on the degree of prolongation, but in general prolongation of 2-fold or more than that in untreated control is considered physiologically significant.

8. Acceptance Criteria

- 8.1 %CV for each control and test sample should be within 5%.
- 8.2 If two duplicates of the same study sample demonstrated results > 5% different, this sample should be reanalyzed.

9. References

1. Dobrovolskaia MA, McNeil SE. Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. *J Control Release*. 2013;172(2):456-66.
2. STart4 Standard operating procedure and training manual. Diagnostica Stago, 26987, June 2002.

10. Abbreviations

ABN	abnormal
API	active pharmaceutical ingredient
APPT	activated partial thromboplastin time
CV	coefficient of variation
N	normal
PT	prothrombin time
SD	standard deviation
TT	thrombin time

11. Appendix

ITA-12 Quick Reference Guide

Assay	Control	Instrument Settings				Volumes		Normal Coagulation Time
		Max Time	Incubation Time	Single/Duplicate	Precision	Plasma and Reagent Volumes	Coagulation Activation Reagent Volumes	
PT (neoplastine)	Coag Control N+ABN	60 sec	120 sec	Duplicate	5%	100 µL Plasma	Neoplastine Reagent: 100 µL (PIP Position 4)	≤ 13.4 sec
APTT	Coag Control N+ABN	120 sec	180 sec	Duplicate	5%	50 µL Plasma + 50 µL PTТА Reagent	CaCl ₂ : 50 µL (PIP Position 2)	≤ 34.1 sec
Thrombine	Coag Control N+ABN	60 sec	60 sec	Duplicate	5%	100 µL Plasma	Thrombine: 100 µL (PIP Position 4)	≤ 21 sec